Short answer
Arcus Biosciences, Inc. (RCUS) filed its Q2 2026 10-Q quarterly report on Aug 5, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $33M (up 312.5% year over year) with net income of −$91M.
Q2 2026 key financials · XBRL
- Revenue
- $33M
- +312.5% YoY · +371.4% QoQ
- Net income
- −$91M
- +28.9% QoQ
- Operating margin
- -290.9%
- EPS (diluted)
- −$0.72
- −1540.0% YoY · +29.4% QoQ
Source: XBRL data from the Arcus Biosciences, Inc. (RCUS) Q2 2026 10-Q on SEC EDGAR. USD.
Arcus Biosciences, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New financing risk: $775 million liquidity projected through at least second half of 2028, contingent on disciplined program prioritization
- Clinical-development risk: Phase 3 STAR-221 discontinued after December 2025 interim analysis showed no benefit over standard of care
- Regulatory risk: FDA may require further studies to demonstrate individual contributions in intra-portfolio combination trials
- Operational risk: Paused etrumadenant development in third-line metastatic colorectal cancer to prioritize late-stage programs
- Debt risk: $100 million drawn under Hercules facility, with minimum-cash covenant beginning July 2027
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Arcus Biosciences, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.